Halozyme Therapeutics Inc (HALO)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$63.50

Buy

$67.29

arrow-up$2.24 (+3.44%)

Prices updated at 19 Dec 2025, 21:25 EST
| Prices minimum 15 mins delay
|
Prices in USD
Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.
NASDAQ
arrow-up1.31%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.

Profit margins

Valuation

Profit margins data table

Year
chevron-l-regular
chevron-r-regular
Gross margin (%)
202484.30
202376.80
202278.90
202181.64
202083.79
201976.76
201893.33
201790.16
201677.36
201578.35

Valuation data table

Year
chevron-l-regular
chevron-r-regular
Price / Sales
20256.58
20246.56
20236.45
202213.90
202112.79
202030.01
201912.70
20187.58
201716.23
20167.91
201519.24
Price/Forward earnings (YTD)
7.77

Returns

Debt profile

Returns data table

Year
chevron-l-regular
chevron-r-regular
Return on assets (%)
202423.39
202315.75
202213.72
202147.82
202022.53
2019-14.36
2018-16.73
201716.12
2016-46.48
2015-18.54

Debt profile data table

YearFinancial leverage
20245.67
202320.68
202210.85
20215.61
20203.84
20196.17
20181.77
20172.50
2016-
20154.23
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.